{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T10:49:21Z","timestamp":1791802161825,"version":"4.3.4"},"reference-count":33,"publisher":"American Association for Cancer Research (AACR)","issue":"10","license":[{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"vor","delay-in-days":11,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Androgen receptor pathway inhibitors (ARPI) are frequently used to treat advanced prostate cancer. Understanding the impact of homologous recombination repair (HRR) alterations on ARPI treatment outcomes is critical for optimizing treatment. We conducted a retrospective analysis of pooled data from five randomized trials of ARPIs (apalutamide or abiraterone acetate) across prostate cancer disease settings. Patients received ARPI-based regimens or androgen deprivation therapy (ADT) alone. HRR alterations were determined using targeted panel or whole-exome sequencing of diagnostic tissue or plasma samples. Radiographic progression-free survival (rPFS) and overall survival (OS) were compared between biomarker groups. Of 608 patients treated with ARPI-based regimens, BRCA-altered patients were at higher risk of progression (HR = 1.8; 95% confidence interval, 1.16\u20132.79; P value = 0.009) and mortality [HR = 1.6 (1.02\u20132.34); P value = 0.038] than those with BRCA wild type. HRR-altered patients had shorter rPFS than HRR wild-type patients [HR = 1.7 (1.2\u20132.3); P value = 0.001]. BRCA-altered patients had shorter OS compared with HRR wild-type patients [HR = 1.6 (1.03\u20132.36); P value = 0.036]. The same results were observed in the full cohort of 878 patients treated with next-generation ARPI or ADT alone. In 115 HRR-altered patients, addition of ARPIs to ADT significantly prolonged rPFS [HR = 0.42 (0.2\u20130.89); P value = 0.023] and OS [HR = 0.45 (0.23\u20130.91); P value = 0.025] versus ADT alone. Although patients with HRR gene alterations benefit from the addition of ARPIs to ADT, they generally have worse outcomes with androgen receptor\u2013directed therapy than HRR wild-type patients, with patients harboring BRCA alterations doing particularly poorly. These findings underline the unmet need for new and combination approaches for these patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>ARPIs are standard-of-care treatment for advanced prostate cancer, but prostate cancer is a molecularly and clinically heterogeneous disease. HRR gene alterations are linked to more aggressive disease. We retrospectively analyzed pooled data from five randomized trials of next-generation ARPIs to assess the impact of HRR alterations on outcomes. Our study highlights an unmet need for improved therapies in patients with HRR-altered prostate cancer treated with ARPIs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-26-0477","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T05:13:37Z","timestamp":1790226817000},"page":"2371-2381","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of\n                    <i>BRCA<\/i>\n                    Alterations on Androgen Receptor Pathway Inhibition Treatment Outcomes in Advanced Prostate Cancer"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-7578-3619","authenticated-orcid":false,"given":"Ruchi","family":"Chaudhary","sequence":"first","affiliation":[{"name":"1Johnson & Johnson Innovative Medicine, Spring House, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5718-4424","authenticated-orcid":false,"given":"Karen A.","family":"Urtishak","sequence":"additional","affiliation":[{"name":"1Johnson & Johnson Innovative Medicine, Spring House, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6438-4141","authenticated-orcid":false,"given":"Michael","family":"Gormley","sequence":"additional","affiliation":[{"name":"1Johnson & Johnson Innovative Medicine, Spring House, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3323-7605","authenticated-orcid":false,"given":"Angela","family":"Lopez-Gitlitz","sequence":"additional","affiliation":[{"name":"2Johnson & Johnson, Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4867-172X","authenticated-orcid":false,"given":"Suneel","family":"Mundle","sequence":"additional","affiliation":[{"name":"3Johnson & Johnson, Raritan, New Jersey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3139-1556","authenticated-orcid":false,"given":"Ademi","family":"Santiago-Walker","sequence":"additional","affiliation":[{"name":"1Johnson & Johnson Innovative Medicine, Spring House, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1724-5093","authenticated-orcid":false,"given":"Sharon","family":"McCarthy","sequence":"additional","affiliation":[{"name":"3Johnson & Johnson, Raritan, New Jersey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5494-4475","authenticated-orcid":false,"given":"Fei","family":"Shen","sequence":"additional","affiliation":[{"name":"1Johnson & Johnson Innovative Medicine, Spring House, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6637-2032","authenticated-orcid":false,"given":"Geoffrey T.","family":"Gotto","sequence":"additional","affiliation":[{"name":"4Southern Alberta Institute of Urology, University of Calgary, Calgary, Canada."},{"name":"5The Vancouver Prostate Centre, University of British Columbia, Vancouver, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,10,12]]},"reference":[{"key":"2026101206294529500_bib1","doi-asserted-by":"publisher","first-page":"3876","DOI":"10.1158\/1078-0432.CCR-10-2815","article-title":"Targeting continued androgen receptor signaling in prostate cancer","volume":"17","author":"Massard","year":"2011","journal-title":"Clin Cancer Res"},{"key":"2026101206294529500_bib2","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1001\/jama.293.17.2095","article-title":"20-year outcomes following conservative management of clinically localized prostate cancer","volume":"293","author":"Albertsen","year":"2005","journal-title":"JAMA"},{"key":"2026101206294529500_bib3","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.cell.2015.10.025","article-title":"The molecular taxonomy of primary prostate cancer","volume":"163","author":"Abeshouse","year":"2015","journal-title":"Cell"},{"key":"2026101206294529500_bib4","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"key":"2026101206294529500_bib5","doi-asserted-by":"publisher","first-page":"11428","DOI":"10.1073\/pnas.1902651116","article-title":"Genomic correlates of clinical outcome in advanced prostate cancer","volume":"116","author":"Abida","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026101206294529500_bib6","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1056\/NEJMoa1603144","article-title":"Inherited DNA-repair gene mutations in men with metastatic prostate cancer","volume":"375","author":"Pritchard","year":"2016","journal-title":"N Engl J Med"},{"key":"2026101206294529500_bib7","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"key":"2026101206294529500_bib8","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly (ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"key":"2026101206294529500_bib9","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N Engl J Med"},{"key":"2026101206294529500_bib10","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"key":"2026101206294529500_bib11","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.ygyno.2017.08.022","article-title":"Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: integrated analysis of data from Study 10 and ARIEL2","volume":"147","author":"Oza","year":"2017","journal-title":"Gynecol Oncol"},{"key":"2026101206294529500_bib12","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N Engl J Med"},{"key":"2026101206294529500_bib13","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in patients with advanced breast cancer and a germline BRCA mutation","volume":"379","author":"Litton","year":"2018","journal-title":"N Engl J Med"},{"key":"2026101206294529500_bib14","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.annonc.2023.06.009","article-title":"Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial","volume":"34","author":"Chi","year":"2023","journal-title":"Ann Oncol"},{"key":"2026101206294529500_bib15","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N Engl J Med"},{"key":"2026101206294529500_bib16","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41591-023-02704-x","article-title":"First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial","volume":"30","author":"Fizazi","year":"2024","journal-title":"Nat Med"},{"key":"2026101206294529500_bib17","doi-asserted-by":"publisher","first-page":"4109","DOI":"10.1038\/s41591-025-03961-8","article-title":"Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial","volume":"31","author":"Attard","year":"2025","journal-title":"Nat Med"},{"key":"2026101206294529500_bib18","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1016\/S1470-2045(18)30456-X","article-title":"Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial","volume":"19","author":"Saad","year":"2018","journal-title":"Lancet Oncol"},{"key":"2026101206294529500_bib19","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"key":"2026101206294529500_bib20","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"key":"2026101206294529500_bib21","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/S1470-2045(21)00402-2","article-title":"Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study","volume":"22","author":"Saad","year":"2021","journal-title":"Lancet Oncol"},{"key":"2026101206294529500_bib22","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1001\/jamaoncol.2019.1011","article-title":"Assessment of the safety of glucocorticoid regimens in combination with abiraterone acetate for metastatic castration-resistant prostate cancer: a randomized, open-label phase 2 study","volume":"5","author":"Attard","year":"2019","journal-title":"JAMA Oncol"},{"key":"2026101206294529500_bib23","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1038\/bjc.2012.451","article-title":"Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer","volume":"107","author":"Abkevich","year":"2012","journal-title":"Br J Cancer"},{"key":"2026101206294529500_bib24","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1158\/2159-8290.Cd-11-0206","article-title":"Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents","volume":"2","author":"Birkbak","year":"2012","journal-title":"Cancer Discov"},{"key":"2026101206294529500_bib25","doi-asserted-by":"publisher","first-page":"5454","DOI":"10.1158\/0008-5472.Can-12-1470","article-title":"Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1\/2 inactivation","volume":"72","author":"Popova","year":"2012","journal-title":"Cancer Res"},{"key":"2026101206294529500_bib26","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1038\/s41391-021-00416-2","article-title":"A transcriptomic model for homologous recombination deficiency in prostate cancer","volume":"25","author":"Weiner","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2026101206294529500_bib27","doi-asserted-by":"publisher","first-page":"6070","DOI":"10.1158\/1078-0432.Ccr-17-0972","article-title":"Gene copy number estimation from targeted next-generation sequencing of prostate cancer biopsies: analytic validation and clinical qualification","volume":"23","author":"Seed","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2026101206294529500_bib28","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1001\/jamaoncol.2021.2350","article-title":"Concordance of DNA repair gene mutations in paired primary prostate cancer samples and metastatic tissue or cell-free DNA","volume":"7","author":"Schweizer","year":"2021","journal-title":"JAMA Oncol"},{"key":"2026101206294529500_bib29","doi-asserted-by":"publisher","first-page":"104738","DOI":"10.1016\/j.ebiom.2023.104738","article-title":"BRCA-deficient metastatic prostate cancer has an adverse prognosis and distinct genomic phenotype","volume":"95","author":"Fettke","year":"2023","journal-title":"EBioMedicine"},{"key":"2026101206294529500_bib30","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.annonc.2024.01.011","article-title":"Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes","volume":"35","author":"Olmos","year":"2024","journal-title":"Ann Oncol"},{"key":"2026101206294529500_bib31","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1016\/j.annonc.2025.05.534","article-title":"BRCA1\/2 and homologous recombination repair alterations in high- and low-volume metastatic hormone-sensitive prostate cancer: prevalence and impact on outcomes","volume":"36","author":"Olmos","year":"2025","journal-title":"Ann Oncol"},{"key":"2026101206294529500_bib32","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.annonc.2022.05.520","article-title":"ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group","volume":"33","author":"Pascual","year":"2022","journal-title":"Ann Oncol"},{"key":"2026101206294529500_bib33","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1158\/0008-5472.CAN-19-3126","article-title":"ATM loss confers greater sensitivity to ATR inhibition than PARP inhibition in prostate cancer","volume":"80","author":"Rafiei","year":"2020","journal-title":"Cancer Res"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-26-0477\/3832528\/crc-26-0477.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/10\/2371\/3837889\/crc-26-0477.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/10\/2371\/3837889\/crc-26-0477.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T10:29:53Z","timestamp":1791800993000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/6\/10\/2371\/788818\/Impact-of-BRCA-Alterations-on-Androgen-Receptor"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":33,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-26-0477","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.34350626","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34350659","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34350638","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34350617","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34350629","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34350644","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34350623","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34350635","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34350614","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34350647","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34350641","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34350620","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34350653","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34350632","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34350650","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.8767718","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]}}}